A Phase 2 interventional study of Enoxaparin and KN060 Low in Knee Arthroplasty, Total, sponsored by Suzhou Alphamab Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Suzhou Alphamab Co., Ltd. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Suzhou Alphamab Co., Ltd. is the lead sponsor of 10 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days post-surgery.
Drug: Enoxaparin
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 low dose once post-surgery.
Drug: KN060 Low
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 middle dose once post-surgery.
Drug: KN060 Middle
Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 hight dose once post-surgery.
Drug: KN060 Hight
40 mg enoxaparin administered as subcutaneous injection once daily
Single dose of KN060 administered as intravenous infusion
Single dose of KN060 administered as intravenous infusion
Single dose of KN060 administered as intravenous infusion
Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral venography, objectively confirmed symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excluded
DVT - Deep vein thrombosis / PE - Pulmonary embolism. All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 days
Incidence of composite endpoint of major and clinically relevant non-major bleeding
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 days
Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral venography, objectively confirmed symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excluded
All suspected events were reviewed and classified by the investigator
Time frame: Up to 35\100 days
Incidence of symptomatic DVT, non-fatal PE
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 \35\100 days
Incidence of fatal PE
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 \35\100 days
Incidence of unexplained death for which PE cannot be excluded
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 \35\100 days
Incidence of composite endpoint of major and clinically relevant non-major bleeding
All suspected events were reviewed and classified by the investigator
Time frame: Up to 35\100 days
Incidence of bleeding
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 \35\100 days
Incidence of major bleeding
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 \35\100 days
Incidence of clinically relevant non-major bleeding
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 \35\100 days
Incidence of treatment emergent adverse event/adverse drug reaction
All suspected events were reviewed and classified by the investigator
Time frame: Up to 14 \35\100 days
Plasma Concentration of KN060
Time frame: Up to 100 days
Pharmacodynamics index: Changes of plasma concentration of Free FⅪ from baseline;
Free FⅪ: Free Factor XI; Factor XI is a clotting factor.
Time frame: Up to 100 days
Pharmacodynamics index: Changes of FⅪ activity from baseline;
FⅪ: Factor XI; Factor XI is a clotting factor.
Time frame: Up to 100 days
Pharmacodynamics index: Changes of APTT from baseline;
APTT: activated partial thromboplastin time;
Time frame: Up to 100 days
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KN060
Suzhou Alphamab Co., Ltd.